Pooled monoclonal antibodies to varicella-zoster virus (VZV) were used as "detector" antibodies in a four-phase enzyme immunofluorescence assay for determination of immunoglobulin M (IgM), IgA In recent years methods for assay of virus-specific immunoglobulin M (IgM) antibody have been advanced which are based on the "capture" of IgM from the test serum by mu chain-specific antibody on a solid phase; virusspecific IgM antibody is detected by subsequent addition of viral antigen followed by enzyme-or radiolabeled viral IgG antibody (5, 10) or by labeled viral antigen (16, 17) . This approach effectively separates IgM from IgG antibodies and some inhibitors and has overcome some of the problems with low sensitivity and specificity that have been encountered in viral IgM antibody assays employing viral antigen bound to the solid phase (3). In the present report we describe a four-phase "capture" assay for IgM antibody to varicella-zoster virus (VZV) which is based on the use of a pool of monoclonal antibodies to VZV (9) as detector antibodies. In addition, we compared the sensitivity of antibody class capture assays (ACCA) with that of solidphase indirect enzyme immunofluorescence assays (EIFA) for detection of VZV antibody of the IgA and IgG classes.
In recent years methods for assay of virus-specific immunoglobulin M (IgM) antibody have been advanced which are based on the "capture" of IgM from the test serum by mu chain-specific antibody on a solid phase; virusspecific IgM antibody is detected by subsequent addition of viral antigen followed by enzyme-or radiolabeled viral IgG antibody (5, 10) or by labeled viral antigen (16, 17) . This approach effectively separates IgM from IgG antibodies and some inhibitors and has overcome some of the problems with low sensitivity and specificity that have been encountered in viral IgM antibody assays employing viral antigen bound to the solid phase (3) . In the present report we describe a four-phase "capture" assay for IgM antibody to varicella-zoster virus (VZV) which is based on the use of a pool of monoclonal antibodies to VZV (9) as detector antibodies. In addition, we compared the sensitivity of antibody class capture assays (ACCA) with that of solidphase indirect enzyme immunofluorescence assays (EIFA) for detection of VZV antibody of the IgA and IgG classes.
MATERIALS AND METHODS
Immune reagents. The production and serological reactivities of VZV monoclonal antibodies have been described previously (9) . The pool of monoclonal antibodies used as detector antibodies in the capture assays consisted of five antibodies (mouse ascitic fluids) with specificities for different glycoproteins of VZV (B. Forghani, K. W. Dupuis, and N. J. Schmidt, submitted for publication). Unlabeled heavy chain-specific goat antisera to human IgM, IgA, and IgG used for ACCA were from Cappel Laboratories, Cochranville, Pa. Alkaline phosphatase-conjugated heavy chainspecific goat antisera to human IgA and IgG used in the solid-phase indirect EIFA were from Miles Laboratories, Elkhart, Ind. Goat anti-mouse immunoglobulin was from Antibodies, Inc., Davis, Calif., and was labeled with alkaline phosphatase as previously described (7, 8) . The optimal * Corresponding author.
working dilution of each immune reagent for use in ACCA or in solid-phase indirect EIFA was determined by preliminary block titration.
Antigens. VZV antigens were prepared from infected human fetal diploid lung cell cultures harvested when they showed a 4-plus viral cytopathic effect. The cells were dislodged into the fluids by shaking with glass beads and then sedimented by centrifugation at 700 x g for 30 min. The supernatant fluid was removed and saved, the cells were resuspended in 1/10 of the original culture volume of the fluid and frozen and thawed three times, and the cell lysate was clarified by centrifugation at 700 x g for 30 min. The remaining infected culture fluid was then added back to the clarified lysate. Control antigen was prepared in parallel from uninfected cell cultures. Antigen prepared in this manner was used for ACCA and for most of the solid-phase indirect EIFA tests for IgA and IgG antibodies. Some EIFA tests were performed with antigens produced from lysates of infected cells as described previously (7); comparable results were obtained with the two types of antigen preparations. Optimal working dilutions of antigen were determined by block titrations against human sera known to be positive or negative for VZV antibodies. The working dilution of antigen used in ACCA was 1:1 or 1:10, and the working dilutions of antigens in solid-phase indirect antibody assays were 1:200 or 1:1,000, depending on the type of antigen preparation.
Solid-phase indirect EIFA. Viral IgA and IgG antibody assays employing antigen in the solid phase were performed as described previously (7), using alkaline phosphataselabeled antibodies to the heavy chains of human IgA or IgG and 4-methyl umbelliferyl phosphate as a fluorogenic substrate (8) .
ACCA. Cups in microtiter plates (Immulon II round bottom; Dynatech Laboratories, Inc., Alexandria, Va.) were sensitized by the addition of goat antibodies specific for the heavy chains of human IgM, IgA, or IgG. Working dilutions were 1:1,500 for the 1gM reagent, 1:1,000 for the IgA reagent, and 1:1,000 for the IgG reagent. The sera were diluted in 0.05 M bicarbonate buffer, pH 9.5, and added in a volume of 0.2 ml per cup. After overnight incubation at room temperature, the contents of the wells were aspirated, and the wells were washed twice with 0.01 M phosphate-buffered saline, pH 7.3 (PBS), containing 0.05% Tween 20, using a washer-aspirator (Dynatech). After the addition of 0.35 ml of 5% bovine albumin in PBS to the wells, plates were held for at least 4 h at room temperature and then washed once with PBS-Tween 20 buffer. The plates were used immediately or stored at -70°C.
Test sera, viral and control antigen, and the pooled VZV monoclonal antibodies were diluted in PBS with 1% bovine serum albumin. Two sets of serum dilutions, starting at 1:16, were prepared in the plates in volumes of 0.1 ml by using microdiluters. After incubation for 1 h at 37°C, the plates were washed three times with PBS-Tween 20 buffer. To one set of serum dilutions was added 0.1 ml of the optimal dilution of viral antigen, and to the other was added 0.1 ml of the same dilution of control antigen. After overnight incubation at room temperature, the plates were washed three times, and the optimal dilution (1:10,000) of the VZV monoclonal antibody pool was added in a volume of 0.1 ml. Plates were incubated for 2 h at 37°C and then washed three times with PBS-Tween 20 buffer. Alkaline phosphatase-labeled goat anti-mouse serum diluted 1:750 in PBS with 3% bovine serum albumin was added in a volume of 0.1 ml, and tests were incubated for 1 h at room temperature. The plates were then washed three times, and 0. (6, 18) , sera were routinely absorbed with aggregated human IgG to remove rheumatoid factor before they were examined for viral classspecific antibodies. This procedure is described in detail elsewhere (6 (Fig. 2) .
Comparison of ACCA and solid-phase indirect EIFA for VZV IgA and IgG antibodies. For those individuals who had class-specific VZV antibodies, Fig. 2 
DISCUSSION
Mouse monoclonal antibodies to human IgM could not be employed as capture antibodies in the four-phase system developed for determination of VZV IgM, as was done for assay of IgM antibodies to certain other viruses (6) . This was because unlabeled mouse monoclonal antibodies to VZV were used to demonstrate binding of viral antigen to VZVspecific IgM on the solid phase, and the labeled antibodies to mouse IgG which were used to detect these would have reacted directly with the capture antibodies in the absence of a virus-specific IgM reaction, giving false-positive results. However, results obtained using a polyclonal anti-human mu chain reagent of goat origin proved to be satisfactory from the standpoint of sensitivity and specificity. A pool of monoclonal antibodies to VZV directed against different viral glycoproteins was used, rather than individual monoclonal antibodies, to impart broader reactivity, and perhaps stronger binding affinity, to the test system. Sensitivity of the VZV IgM antibody assay was evidenced by the fact that high titers of virus-specific IgM were demonstrated for all of the patients with varicella. Only onehalf of the patients with zoster showed an IgM antibody response, and titer levels varied widely. The frequency with which IgM antibody responses to VZV have been demonstrable in patients with zoster has shown wide variation in studies employing different assay procedures (1, 4, 11, 12, 14, 15, 17) . However, in recent studies with sensitive immunoassays which have taken into account the possible role of rheumatoid factor in producing false-positive results, IgM antibody responses have been demonstrable in 50 to 80% of zoster patients studied (1, 4, 11, 17) . More comparative studies are needed on the sensitivity and specificity of different assay systems for detection of VZV IgM antibodies in zoster patients, and such studies should provide a better understanding of the humoral immune response to reactivated VZV infections. In the present studies the importance of using uninfected control antigens in viral ACCA systems was indicated by the fact that three individuals without current VZV infections reacted with the control antigen to the same level as to viral antigen, and in the absence of an uninfected antigen control, the test results would have been misinterpreted as being specific for VZV IgM antibody.
Specificity of the VZV IgM antibody assay was indicated by the fact that negative results were obtained with sera from initial HSV infections, from patients with clinical illnesses other than VZV infection, from adults with latent VZV infection, and from young children who were seronegative for VZV IgG antibodies. The The ACCA for VZV IgA antibodies did not show promise for detection of active VZV infection, since IgA antibody responses in the varicella and zoster patients varied considerably in frequency and magnitude. Low titers and variable IgA antibody responses to VZV have also been noted in certain other studies (2, 4, 13) .
The sensitivity of ACCA depends on a high proportion of the total immunoglobulin class being virus specific. This is the case with viral IgM antibody in acute viral infections. Although ACCA for VZV IgA antibodies gave variable titers for varicella and zoster patients, the titers obtained by this procedure were higher than those determined by solid-phase indirect EIFA, indicating that a fairly high proportion of the total serum IgA is virus specific in many VZV infections. VZV IgG titers determined by ACCA were comparable to those obtained by solid-phase indirect EIFA for varicella patients and to a lesser extent for zoster patients. On the other hand, ACCA was totally insensitive for determination of VZV IgG elicited by past infections, which apparently constituted only a small proportion of the present IgG class of the individuals. Thus, ACCA is not a suitable approach for determination of VZV immunity status. 
